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Abstract. The objective of this paper is to study the differences in tumor size, color score and 
Doppler indices prior, during and after the treatment with concurrent chemoradiotherapy in cases 
of locally advanced cervical carcinoma and to predict the response to the treatment. The study 
group comprised fifty-two patients with histologically confirmed invasive carcinoma of the 
cervix. All patients were scheduled for concurrent chemoradiotherapy and were assessed by 
transvaginal ultrasound before the initiation, before 4th course of chemotherapy and 3 months 
after the therapy. Maximum cervical tumor length, anterior-posterior diameter and width have 
been measured and tumor volume was calculated. Complete clinical response (CR) was defined 
when no residual tumor was found. Partial clinical response (PR) was determined when the tumor 
volume had decreased more than 50 %. Intratumoral blood flow was subjectively evaluated by 
Color Doppler examination, the lowest resistance index (RI) and the highest peak systolic velocity 
(PSV) were used for the analysis. The results of this study demonstrate that transvaginal 
ultrasound is a valuable non-invasive diagnostic tool for the assessment of the response to 
concurrent chemoradiotherapy in cases of advanced cervical cancer. 
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1. Introduction 
Cervical cancer is a major health problem. There were 33 thousand new cases of cervical 
cancer diagnosed in European Union in 2012, and 22 thousand of women died of this disease [1]. 
In Lithuania, the morbidity and mortality of cervical cancer is one of the highest in European 
Union. In the last five years, the morbidity in Lithuania remains in the interval of  
25.6-29.2/ 100 000 women per year. There were 431 new cases of cervical cancer in Lithuania in 
2012, and 35.5 % of them were diagnosed in advanced stages. The mortality of this disease in 
Lithuania is 12.9/100 000 women per year, exceeding that in EU by almost three times [1, 2]. 
The treatment strategy depends on the extension of the disease. While early stages (FIGO  
I-IIA) of invasive cervical cancer can be successfully treated by radical surgery, the treatment of 
advanced disease (from the stage II B) is complex, consisting of concurrent chemoradiotherapy 
(distant radiotherapy of the pelvis with concurrent chemotherapy once a week) [3].  
It is quite essential to assess the effectiveness of concurrent chemoradiotherapy and to proceed 
with the management of cases with residual disease as soon as possible. However, the evaluation 
of the treatment response remains a complicated task. It has been suggested magnetic resonance 
imaging (MRI) to be a “gold standard” in monitoring the effectiveness of chemoradiotherapy; 
however, it is expensive and time-consuming method herewith in developed EU countries. 
Ultrasound (US) is inexpensive, harmless method that could be carried out quickly and could 
be used to monitor the effectiveness of cervical cancer treatment widely as alternative method to 
MRI. In the grey scale, volumetric parameters of the tumour can be measured, while during 
Doppler examination the vascularity and blood flow (the resistance index (RI), colour score (CS), 
peak systolic velocity (PSV)) could be assessed. 
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The aim of this study is to evaluate the differences in tumour size, colour score and Doppler 
indices prior, during and after the treatment with concurrent chemoradiotherapy in cases of 
invasive cervical carcinoma to predict the response to the treatment. 
2. Methods 
The local ethics committee approved the study (Permission No. 146/2004), and all 
participating patients consented to the study protocol in writing. Prospective observational study 
was performed. All patients diagnosed with primary advanced stage (FIGO IB2-IIIB) cervical 
carcinoma and treated at Lithuanian University of Health Sciences Hospital Kaunas Clinics, 
Gynaecology Department during the period of 2009-2011 were included in the study. The study 
was combined of three steps of ultrasound examination – prior the concurrent chemoradiotherapy 
(Step I), during the treatment – before the fourth course of chemotherapy (Step II) and three 
months after the treatment (Step III) (Fig. 1). 
 
Fig. 1. Study design 
The ultrasound examination was standardized. It was performed using “Toshiba Xario” 
(“Toshiba Medical Systems”, Tokyo, Japan) ultrasound machine with transvaginal microconvex 
ultrasound probe Toshiba PVT-661VT (frequency range of 3.6-8.8 MHz), covered with 
disposable plastic cover instilled with sonogel (Parkers Inc., USA) (Fig. 2). The examination of 
patients consisted of two stages – grey scale examination and Doppler examination (using selected 
frequency of 6.0 MHz and 7.0 MHz). 
The patients were examined in the lithotomy position with an empty bladder. The cervical 
tumour was identified as an area of solid, mostly hypoechoic lesion in contrast with surrounding 
cervical stroma or paracervical tissue. In the sagittal plane the maximum craniocaudal length (L) 
and the maximum antero-posterior diameter (AP) of the tumour were measured. Then the 
ultrasound probe was rotated in 90 angle degree and transversal plane of the cervical tumour was 
obtained and the maximum width (W) was measured (Fig. 3). All morphometric characteristics of 
the tumour were measured minimum three times and the maximum dimensions of the tumour were 
analysed [7]. The volume of the tumour was calculated using formula for prolate ellipse:  
L × AP × W × ߨ/6, and expressed in cm3 [4]. The vascularity of the cervical tumour was determined 
by colour Doppler technique described by A. C. Testa et al. [8]. 
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Fig. 2. Ultrasound equipment: a) TOSHIBA Xario XG ultrasound mashine and  
b) TOSHIBA PVT-661VT endovaginal Ultrasound Probe 
 
Fig. 3. Measurements of invasive cervical carcinoma: a) sagittal plane and b) transverse plane 
The colour score was subjectively determined using highest sensitivity of colour Doppler 
signal, which allowed the detection of blood flow velocities ൒ 3 cm/s and the colour gain was set 
just below the background noise level to increase the Doppler sensitivity for low-velocity flow 
detection. A colour score from 1 to 4 was given, 1 meaning no blood flow, 2 – minimal blood flow 
present in the tumour, 3 presented moderate vascularity and 4 – highly vascular tumour [8]. After 
the vessel was identified, the Doppler sample gate was placed over it to obtain the flow velocity 
waveform [5]. The resistance index (RI) was automatically calculated as the difference between 
peak-systolic and end-diastolic frequency shifts divided by the peak-systolic frequency shift 
(Fig. 4) [5, 9]. The PSV was also automatically calculated. The maximum PSV and the lowest RI 
found for each tumour were used in analysis. 
After the Step III ultrasound examination (3 months after the chemoradiotherapy, all patients 
were divided into three groups (Fig. 5): 
• complete response – when no residual tumour was found; 
• partial response – when the tumour volume has decreased more than 50 %  
• no response – when decrease in tumour size was less than 50 %.  
Statistical analysis was performed using “SPSS 22.0” statistical analysis program. The ݌ value 
≤ 0.05 was considered statistically significant. Student’s t-test was used for two paired samples 
comparison. 
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Fig. 4. Doplerometry example of tumour blood flow 
 
Fig. 5. Subgroups according to ultrasound findings after the treatment 
3. Results 
A total number of 79 patients were included in the study, however, 27 patients were withdrawn 
due to different reasons and 52 fully completed the study protocol (Fig. 2). The median age of the 
patients was 46 years, ranging from 28 to 76 years. 17 (32.7 %) patients were diagnosed with IB2 
stage (FIGO) cervical cancer and 35 (67.3 %) with stage IIA or higher. Histologically, 41 (78.9 %) 
cases were squamous cell carcinoma, 10 (19.2 %) – adenocarcinoma and 1 (1.9 %) – adeno 
squamous carcinoma. 13 (25 %) were well differentiated tumours (Grade 1), 27 (51.9 %) – 
moderately differentiated (Grade 2) and 12 (23.1 %) – poorly differentiated tumours (Grade 3). 
All main characteristics of the patients are shown in the Table 1. 
CR according US examination was achieved in 28 patients (54 %), whereas 22 (42 %) patients 
demonstrated partial response. In 2 (4 %) cases decrease in tumour size was less than 50 % (no 
response group). In one of these two cases the relapse of the disease was quickly diagnosed – 
distant metastasis was found in lungs and liver (confirmed on computer tomography). Despite the 
treatment, patient died in the period of six months. 
The morphometric analysis showed that the mean tumour volume was not significantly 
different between CR and PR groups at the beginning of the treatment (Step I ultrasound exam) – 
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28.1 vs. 31.3 cm3, ݌ = 0.64. Nevertheless, tumour volume in CR group was significantly lower 
compared with PR group (19.2 vs. 26.9, ݌ = 0.003) at the middle stage of the treatment (Step II 
ultrasound exam) (Table 2). 
The Mode of colour score before and during the treatment was 4, after the treatment – 2. A 
significantly lower colour score when compared to initial evaluation was found after the treatment 
in the group with CR (݌ = 0.007), whereas there was no difference observed in the group with PR 
(Fig. 6). 
There was a significant difference of RI between the CR and PR groups before the treatment 
(0.53 vs. 0.68; ݌ = 0.045). Analysis of vascular indices in CR groups showed that RI after the 
treatment was significantly higher compared with RI before the treatment. Whereas, no significant 
RI changes were noted in PR group (Table 3).  
Table 1. Characteristics of the patients and tumours included in this study (݊ = 52) 
Characteristic Median (range) or ݊ (%) 
Patient age (years) 46 (28-76) 
Stage (FIGO): 
• IB2 
• IIA and higher 
 
17 (32.7) 
35 (67.3) 
Histology: 
• Squamous cell carcinoma 
• Adenocarcinoma 
• Adeno squamous carcinoma 
 
41 (78.9) 
10 (19.2) 
1 (1.9) 
Grade: 
• G1 
• G2 
• G3 
 
13 (25) 
27 (51.9) 
12 (23.1) 
Table 2. Changes in tumour volume (cm3) between the CR and PR groups  
during the course of treatment, mean (SD) 
 Before Mid  
CR group 28.1 (6.8) 19.2 (2.2) - 
PR group 31.3 (7.9) 26.9 (3.8)* 5.7 (2.7) 
* statistically significant difference between CR and PR groups in the mid treatment, ݌ = 0.003 
Table 3. Changes of resistance index (RI) between the CR and PR groups  
during the course of treatment, mean (SD) 
 Before Mid Post 
CR group 0.53 (0.19) 0.61 (0.21) 0.79 (0.11)* 
PR group 0.68 (0.16)** 0.63 (0.16) 0.77 (0.22) 
*statistically significant difference of the RI before and after the treatment in the CR group, ݌ = 0.03 
**statistically significant difference of the RI between CR and PR groups before the treatment, ݌ = 0.045 
The PSV was significantly lower in CR group than in PR group before the treatment (16.6 vs. 
21.3; ݌ = 0.04). After the treatment, the PSV was found significantly decreased in both groups: 
the CR group (8.2 vs. 16.6; ݌ < 0.001) and the PR group (10.9 vs. 21.3; ݌ < 0.001) (Table 4). 
Table 4. Changes of peak systolic velocity (PSV, cm/s) between the CR and PR groups  
during the course of treatment, mean (SD) 
 Before Mid Post 
CR group 16.6 (3.9) 18.1 (4.1) 8.2 (2.1)* 
PR group 21.3 (3.2)** 19.2 (3.2) 10.9 (1.3)* 
*statistically significant difference of the PSV before and after the treatment in the CR and PR groups 
separately, ݌ < 0.001 
**statistically significant difference of the PSV between CR and PR groups before the treatment, ݌ = 0.04 
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a) CR group 
 
b) PER group 
Fig. 6. Changes in color score (CS) during the treatment in CR and PR groups 
4. Discussion 
Until now, there is no confirmed and scientifically proven agreement on how to evaluate the 
effectiveness of concurrent chemoradiotherapy for cervical cancer treatment and how to diagnose 
the cases of inefficient treatment at the optimal time intervals. In the clinical practice the MRI 
and/or ultrasound are two most often used methods. Despite this fact, there is no unanimous 
opinion neither on capability of these methods, nor on the parameters that should be estimated to 
reliably monitor patients undergoing this treatment. 
In our study, we compared the changes of morphometric and vascular parameters of cervical 
tumours during the course of concurrent chemoradiotherapy. The tumour parameters were 
compared between subsequent complete and partial response groups depending on the residual 
tumour mass seen on the ultrasound scan three months after the treatment. The latter study design 
was used in other studies as well [5], however it is speculative and quite precarious because 
cervical lesions interpreted as “residual tumour mass” on the ultrasound, were not histologically 
verified by performing the true-cut biopsy or hysterectomy. That is the main weakness of this 
study; however, it is the case in the vast majority of other studies, which have employed either 
ultrasound or MRI [5, 6]. 
The morphometric parameters of the cervical tumour were evaluated on the grey scale 2D 
ultrasound. In agreement with J. L. Alcazar et al., the initial tumour volume didn’t differ between 
the subsequent complete and partial response groups [5], suggesting that the volume of primary 
disease has no influence on the changes of the tumour mass during proceeded concurrent 
chemoradiotherapy. However, in the group of complete response chemoradiotherapy results in the 
fast decline in tumour mass, which results in significantly lower tumour volumes and is not 
observed in the group of partial response. Thus, the speed of tumour mass regress should be 
considered as a prognostic factor. The more prominent indicator of inferior treatment effectiveness 
could be the identification of the residual mass after the treatment. In our study, 24 (48 %) cases 
demonstrated the “residual disease”, however, we do not dare to speculate that all of them had 
been left with an alive tumour and were in danger to relapse. This should be confirmed by future 
studies. 
In 1999, it was suggested by J. L. Alcazar that transvaginal Doppler ultrasound might be used 
to predict treatment response of concurrent chemoradiotherapy in cases of invasive cervical cancer 
[4]. Only few studies addressed that issue [5, 6] and until now there is no unanimous opinion 
which parameters of doplerometry are more accurate, have higher diagnostic or prognostic value. 
It has been observed that tumours with subsequent partial response to the therapy demonstrated 
higher vascularity and lower RI [4-6]. It has been suggested that the cut-off of RI 0.35 or lower 
could be used to predict partial response to the chemoradiotherapy [5]. Contrary, we found RI 
before the treatment to be significantly lower in CR compared to PR group. After the treatment, 
the resistance increased in both groups, however, only in CR group these changes were statistically 
significant. The significant difference in PSV between the groups of CR and PR before the 
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treatment has been observed in our study suggesting that high PSV values could predict a poorer 
response to the treatment. However, this was not observed by others [4, 5]. The discrepancies of 
RI and PSV studies could be explained by the complicated technique, which requires the 
acquisition of Doppler indices in somehow arbitrary way. We completely disagree with 
U. Kerimoglu et al., who proposed to use Doppler indices for the assessment of treatment response 
as more reliable technique than grey scale sonography or subjective assessment of colour score. It 
was demonstrated by our findings that remaining high colour score indices after the treatment 
could predict an inferior response to the chemoradiotherapy.  
According to results of ultrasound examination, we defined a group of patients with local 
residual lesions. However, without a histological confirmation it is impossible to decide if these 
lesions mean a residual disease. It must be noticed that the study of similar structure should be 
performed where suspected residual tumour mass on ultrasound exam would be verified by 
histological examination. Moreover, it is an object of further studies to define the proper 
management of these patients. Yet, we dare to suggest that patients with suspected partial response 
after the treatment: residual tumour mass on grey scale ultrasound examination, highly expressed 
tumour vascularity (CS of 3 or 4) and low resistance indices should be taken under thorough 
surveillance.  
Joana Celiesiute – main researcher; Adrius Gaurilcikas – main researcher; Migle Gedgaudaite 
– literature research and statistical part; Saulius Paskauskas – statistical work; Kristina Jariene – 
researcher; Daiva Vaitkiene – scientific supervisor. 
5. Conclusions 
The results of our study demonstrate that transvaginal ultrasound is of value as a non-invasive 
diagnostic tool for the assessment of the response to concurrent chemoradiotherapy in cases of 
advanced cervical cancer. 
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